Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
Want to see GLMD full AI Analyst Report?
GLMD Stock Chart & Stats
$0.79
-$0.05(-1.56%)
At close: 4:00 PM EST
$0.79
-$0.05(-1.56%)
Day’s Range― - ―
52-Week Range$0.41 - $2.34
Previous CloseN/A
Volume19.24K
Average Volume (3M)84.25K
Market Cap
$4.04M
Enterprise Value$144.15K
Total Cash (Recent Filing)$18.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding6,599,654
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$5.72M
Bulls Say, Bears Say
Bulls Say
Lead Asset: Improved Oral FormulationA ~5x bioavailability oral formulation meaningfully raises systemic exposure, can lower manufacturing costs, and supports broader dosing for new indications. This strengthens Aramchol's clinical utility, extends IP/market exclusivity, and improves the drug's long-term competitive positioning and trial feasibility.
CNS Expansion With Brain‑penetrant AramcholA brain‑penetrant formulation opens durable strategic optionality beyond liver disease into high‑unmet‑need CNS markets (e.g., Parkinson’s). This diversifies addressable markets, leverages existing SCD1 biology, and creates a longer‑term platform opportunity for disease‑modifying therapies if translational work succeeds.
Human‑relevant Preclinical Partnerships And PatentingPartnerships using high‑throughput human organoids and AI accelerate target validation and IND‑enabling work, improving translational predictivity. Combined with new patent activity, this builds durable R&D advantages, shortens preclinical timelines, and enhances the company's ability to de‑risk and expand Aramchol indications.
Bears Say
No Revenue And Persistent Net LossesThe absence of product revenue and repeated net losses mean margins are undefined and profitability remains distant. Over the medium term this constrains reinvestment capacity, increases reliance on capital markets, and makes operational planning dependent on successful trials or external financing rather than internal cash generation.
Negative Operating And Free Cash FlowSustained negative cash flow requires recurring external funding, which can dilute shareholders and divert management focus to financing. It limits runway for clinical programs, raises execution risk for multi‑year development plans, and reduces flexibility to scale trials or commercial efforts without partner capital.
Acquisition Adds Going‑concern And Integration BurdenAcquiring Colospan requires $6M committed investment and integration of a company with going‑concern doubts. This structurally increases cash burn, execution complexity, and near‑term financing needs, risking distraction from Aramchol development and pressuring the balance sheet and dilution over the next 2–6 months.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $0.41 and its highest was $2.34 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $4.04M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on May 20, 2026. The company reported -$0.38 earnings per share for the quarter, the consensus estimate of -$0.38 by $0.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate is -0.39.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 6,599,654 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, expectations of -$0.38. Following the earnings report the stock price went up 5.226%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes. Aramchol is also being investigated in the Phase IIa ARRIVE Study, which targets HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Beyond Aramchol, the company is developing Amilo-5MER, a synthetic peptide composed of five specific amino acids: methionine, threonine, alanine, aspartic acid, and valine. Galmed has established several strategic collaborations, including: A research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH, merging ASC41 (a THR-beta agonist) with Aramchol (an SCD1 inhibitor). A research and development partnership with MyBiotics Pharma Ltd. to identify specific microbiome profiles linked to how patients respond to Aramchol. A licensing agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in South Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is based in Tel Aviv, Israel.
GLMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AIM ImmunoTech
―
Jaguar Animal Health
―
Quoin Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.08% Mutual Funds
<0.01% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---